By Medicine

ACE Inhibitor (Enalapril 2.5 - 20mg/day (uptitrated as tolerated) va placebo, CKD

ACE Inhibitor (Enalapril 2.5 - 20mg/day (uptitrated as tolerated) vs placebo, heart failure

ACE Inhibitor (Enalapril 2.5 - 40mg/day (uptitrated as tolerated) vs placebo, asymptomatic heart failure

ACE Inhibitor (Enalapril 2.5 - 40mg/day uptitrated as tolerated) vs placebo, severe heart failure

ACE Inhibitor (Ramipril 10mg/day) vs placebo (high-risk of cardiovascular disease without LVSD or heart failure)

ACE Inhibitor and Indapamide (Perondopril 4mg/day and Idapamide 2.5mg/day) vs placebo

Alendronate 10mg tablets vs placebo

Alendronate vs placebo

Angiotensin II receptor antagonist (Telmistartan 80mg/day) vs placebo

Angiotensin II receptor blocker (Candesartan 4-32mg/day)

Antiplatelet, placebo or no treatment

Apixaban 5mg twice daily vs Warfarin (to maintain an INR OF 2-3), non-valvular AF - major bleeding

Apixaban 5mg twice daily vs Warfarin (to maintain an INR OF 2-3), non-valvular AF-stroke or systemic embolism

Aspirin & Dipyridamole vs Aspirin

Aspirin & Dipyridamole vs placebo

Aspirin or other antiplatelet vs placebo or no treatment

Aspirin vs placebo or no treatment

Betablocker (Bisoprolol titrated to target dose of 10mg/day) vs placebo

Betablocker (carvedilol titrated to target dose of 25mg twice daily) vs placebo

Betablocker (Metoprolol modified release titrated to a target dose of 200mg/day) vs placebo

Betablocker (Nebivolol titrated to a target dose of 10mg/day) vs placebo

BP control (<140/90mmhg) patient with hypertension and age> 80yrs

BP control (<140/90mmhg) patients with hypertension and >60 years

BP control (<140/90mmhg) patients with hypertension high risk and >60 years

BP control (<140/90mmhg) patients with hypertension high risk and greater than 80 years

Dabigatran 110mg or 150mg twice daily vs Warfarin (to maintain an INR OF 2-3), patients with non valvular AF, major bleeding

Dabigatran 110mg or 150mg twice daily vs Warfarin (to maintain an INR OF 2-3), Patients with non valvular AF, stroke or systemic embolism

Direct Acting Oral Anticoagulants (DOACs)

Edoxaban mg or 60mg daily vs Warfarin (to maintain an INR OF 2-3), patients with non valvular AF, stroke or systemic embolism

Edoxaban mg or 60mg daily vs Warfarin (to maintain an INR OF 2-3), patients with non valvular AF, major bleeding

Intensive control of glucose vs hypoglycaemia agents chosen by the treating physician

Intensive Sulphonylurea with insulin vs conventional treat with diet

Metformin-achieve fasting blood glucose <6.0MMOL/L Vs diet alone-achieve fasting blood glucose <15MMOL/L.

Rivaroxaban 20mg daily vs Warfarin (to maintain an INR OF 2-3), patients with non valvular AF, major bleeding

Rivaroxaban 20mg daily vs Warfarin (to maintain an INR OF 2-3), patients with non valvular AF, stroke or systemic embolism

Spironolactone 25mg daily vs placebo

Statin (Simvastatin 40mg daily, Atorvastatin 80mg daily, Pravastatin 40mg daily) vs placebo, serious vascular events

Statin (Simvastatin 40mg daily, Atorvastatin 80mg daily, Pravastatin 40mg daily) vs placebo, stroke

Thienopyridine derivative (Ticlopidine or Clopidogrel) vs Aspirin, stroke (all types)

Thienopyridine derivative (Ticlopidine or Clopidogrel) vs Aspirin, stroke, MI, or vascular death

Warfarin (Target INR 2 - 3) VS Asprin 75mg daily